Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The ...

The personalized cancer vaccine market is gaining rapid momentum, driven by biotech advancements and rising demand for targeted immunotherapies. The new 2025 report analyzes key players like BioNTech, ...